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Objectives. Type 1 and 2 diabetes carry risk factors for the development of microvascular diseases with associated impairment
of angiogenic repair. Here, we investigated whether adiponectin, an adipocyte-specific adipocytokine with antiatherosclerotic
and antidiabetic properties, regulates angiogenic repair in response to tissue ischemia in Leprdb/db and streptozocin-treated
diabetic mouse models. Methods. Adenoviral vectors containing the gene for β-galactosidase, full-length mouse adiponectin,
and dominant-negative AMPKα2 were used in streptozocin-treated male Leprdb/db mice, after which hind limb blood flow was
measured using a laser doppler blood flow analyzer. Results. The angiogenic repair of ischemic hind limbs was impaired in both
streptozocin-treated and Leprdb/db mice compared to wild-type mice as evaluated by laser doppler flow and capillary density
analyses. Adenovirus-mediated administration of adiponectin accelerated angiogenic repair after hind limb ischemia in WT mice,
but not in Leprdb/db mice or mice treated with streptozocin. In vitro experiments using HUVECs highlighted the antiapoptotic
and proangiogenic properties of adiponectin but could not demonstrate accelerated diﬀerentiation of endothelial cells into tube-
like structures at elevated glucose levels. Conclusions. External administration of adiponectin at elevated glucose levels may not be
useful in the treatment of diabetes mellitus-related vascular deficiency diseases.
1. Introduction
Type 1 diabetes is caused by absolute insulin deficiency,
whereas glucose intolerance and peripheral insulin resis-
tance characterize Type 2 diabetes. Type 2 diabetes often
occurs in patients displaying a combination of clinical
and biochemical symptoms [1–4]. Both types of diabetes
are associated with microvascular rarefaction and reduced
collateralization in ischemic tissues. These circulatory deficits
often lead to ischemic injury and impaired wound heal-
ing. However, the mechanisms by which diabetes inhibits
angiogenic repair in ischemic tissues are poorly under-
stood.
Adiponectin/ACRP30 is a circulating adipocyte-derived
cytokine whose levels are decreased in patients with obesity,
diabetes, and coronary artery diseases [5–8]. Adiponectin
is known to promote insulin sensitivity by decreasing
triglyceride content in muscle and liver in obese mice [9–
13]. Triglycerides are reduced primarily through the regu-
lation of enzymes involved in both fatty-acid combustion
and energy dissipation. Adiponectin reduces atherosclerotic
lesions in apolipoprotein E-deficient mice and has anti-
inflammatory eﬀects on the vasculature [14–16]. It has
been shown that adiponectin acts upon endothelial cells to
promote angiogenesis and that ischemic-induced neovas-
cularization is impaired in adiponectin-deficient mice [17,
18]. Adiponectin reportedly also protects endothelial cells
from apoptosis [19, 20]. Nevertheless, the administration
of adiponectin for therapeutic angiogenic repair in the
context of diabetes-related vascular deficiency has not been
evaluated.
In this study, we investigated whether adiponectin mod-
ulates the angiogenic recovery process in the ischemic hind
limbs of streptozocin-treated and Leprdb/db mice.
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Insulin deficiency was induced by intraperitoneal admin-
istration of the β-cell toxin streptozocin (db1 mice) [21, 22].
The mouse model for Type 2 diabetes employed the db/db
mouse strain, a strain that lacks a functional leptin receptor
[23]. These mice become identifiably obese at 3 to 4 weeks
of age [24–26]. Elevation of plasma insulin begins at 10 to
14 days and of blood sugar at 4 to 8 weeks. These mice are
polyphagic, polydipsic, and polyuric.
Here we show that when compared to control mice,
both mouse models of diabetes have impaired angiogenic
repair following hind limb ischemic surgery. In both diabetes
models adiponectin treatment was evaluated for its ability to
stimulate angiogenic repair. Our observations indicate that
administration of adiponectin may not be instrumental in
the treatment of vascular deficiency disease associated with
chronic hyperglycemia.
2. Materials andMethods
2.1. Materials. Recombinant human vascular endothelial
growth factor (VEGF) was purchased from Sigma (St. Louis,
MO, USA). The use of recombinant adiponectin, adenovirus
vectors containing the gene for β-galactosidase (Ad-βgal),
full-length mouse adiponectin (Ad-APN), and dominant-
negative AMPKα2 (Ad-dnAMPK) was described previously
[17, 27, 28].
2.2. Mouse Models
Streptozocin-Treated Mice. Diabetes was induced by intra-
peritoneal injection of STZ (= streptozocin) in male wild-
type mice in a C57/BL6 background at 4 weeks of age.
Streptozocin was administered at 60mg/kg, freshly dissolved
in 0.05M sterile sodium citrate, pH 4.5 on 6 subsequent
days [21, 22]. Control animals received sodium citrate only.
Diabetes was verified 16–25 days later by measuring blood
glucose levels in samples drawn from the tail vein using
blood glucose test sticks and a conventional glucometer
(Hypoguard, Minneapolis, Minnesota, USA).
In the first 2 weeks after onset of diabetes blood glucose
levels were measured daily. If glucose levels occasionally
recovered, an additional STZ injection was given on days
25–27. More than 90% of mice became diabetic within the
first 4 weeks. Insulin injection started as soon as blood
glucose increased above 300mg/dL and was administered
as individual injection of 1-2 units of Insulin Ultralente
(100U/mL; Lilly, Indianapolis, USA). After blood glucose
levels stabilized, blood glucose levels were measured at a
minimum of once a week. Despite insulin replacement, the
mice remained hyperglycemic with serum glucose val-
ues >200mg/dL. The outcomes observed in STZ-treated
C57/BL6 mice were compared with untreated C57/BL6 mice.
Lepr(db/db) Mice. Male Leprdb/db mice in a C57/BL6 back-
ground andmale wild-type (WT)mice (C57/BL6) purchased
from The Jackson Laboratory were used for this study. The
outcomes observed in Leprdb/db mice were compared to
C57/BL6 mice as controls.
At the age of 8 weeks, mice were anesthetized with
sodium pentobarbital (50mg/kg intraperitoneal) and sub-
jected to unilateral hind limb surgery [29, 30]. An incision
was performed in the dermis overlying the middle portion
of the left hind limb. After ligation of the proximal end
of the femoral artery, the distal portion of the saphenous
artery was ligated, and the artery, as well as all side branches,
was dissected free and excised. The skin was closed using a
surgical stapler. Before surgery, body weight (BW) was deter-
mined, and systolic blood pressure (sBP) was determined
using a tail-cuﬀ pressure analysis system while mice were in
the conscious state.
In some experiments, 2 × 108 plaque-forming units
(PFU) of adenoviral vector encoding adiponectin (Ad-APN)
or β-galactosidase (Ad-βgal) were injected into the jugular
vein of mice 3 days prior to the ischemic hind limb. For
adenovirus experiments ischemic/nonischemic laser doppler
blood flow (LDBF) ratios were examined at 14 days after
surgery, which is compatible with the time course of
adenovirus-mediated gene expression.
2.3. SerumMeasurement. Blood samples were collected from
the tail vein on the day of surgery. Glucose was measured
with an enzymatic kit (Wako Chemicals, Richmond, Vir-
ginia, USA). Leptin levels were measured with mouse leptin
enzyme-linked immunosorbent assay (ELISA) kit (Crys-
tal CHEM INC, Downers Grove, Illinois, USA). Mouse
adiponectin levels were determined with an adiponectin
ELISA kit (Otsuka Pharmaceutical Co Ltd, Tokyo, Japan).
For adiponectin, blood samples were collected from tail vein
at the time of hind limb surgery, which was 3 days after the
administration of the adenoviral vectors.
2.4. Laser Doppler Blood Flow Analysis. After anesthesia, hair
was removed from both legs using a depilatory cream. Mice
were then placed on a heating plate at 37◦C for 10 minutes to
minimize temperature variations. Hind limb blood flow was
measured using a laser doppler blood flow (LDBF) analyzer
(Moor LDI; Moor Instruments, Devon, United Kingdom).
Immediately before surgery, immediately after surgery, and
on postoperative days 3, 7, and 14 LDBF analyses were
performed on legs and feet. Blood flow was displayed as
changes in the laser frequency using diﬀerent color pixels.
After scanning, stored images were analyzed to quantify
blood flow. To avoid data variations due to ambient light and
temperature, hind limb blood flow was expressed as the ratio
of left (ischemic) to right (nonischemic) LDBF.
2.5. Tissue Preparation and Immunohistochemistry. The mice
were sacrificed with an overdose of sodium pentobarbital.
For immunohistochemistry, muscle samples were imbedded
in optimal cutting temperature (OCT) compound (Miles,
Elkhart, Indiana, USA) and snap-frozen in liquid nitro-
gen. Tissue slices (5 μm in thickness) were prepared, and
immunohistochemistry was performed using antibodies for
CD31 (PECAM-1: Becton Dickinson, Franklin Lakes, New
Jersey, USA). Capillary density within the adductor muscle
was quantified by histological analysis. Fifteen randomly
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chosen microscopic fields from three diﬀerent sections in
each tissue block were examined for the presence of capillary
endothelial cells for each mouse specimen. Capillary density
was expressed as the number of CD-31-positive features per
high power field (×400) and the number of capillaries per
muscle fiber.
2.6. Cell Viability Assays. Human umbilical vein endothe-
lium cells (HUVECs) were purchased from Cambrex Bio
Science, Walkersville, MD, USA. The CellTiter 96 AQueous kit
(Promega, Madison, Wi USA) was used to assess cell viability
according to the manufacturer’s instructions using a non-
radioactive cell proliferations assay (MTS) reagent. Briefly,
HUVECs were plated at a density of 1.5 × 104 cells/well
in a 96-well plate and incubated in growth media for 18
hours. Cells were treated with indicated concentrations
of D-glucose (or D-mannitol as osmolarity control) and
recombinant adiponectin or 10 ng/mL VEGF in endothelial
basal medium-2 (Cambrex Bio Science, Baltimore, USA)
containing 0.5% fetal calf serum (FCS) for 48 hours. In
some experiments HUVECs were infected with adenoviral
constructs encoding β-galactosidase (Ad-βgal) or dominant-
negative AMPKα2 (Ad-dnAMPK) at a multiplicity of infec-
tion of 50 for 24 h [17, 27, 28, 31]. The 490 nm absorbance
was measured after two more 1-hour incubations with MTS.
The percentage of cell death was calculated as the decrease in
absorbance relative to cells incubated in 20% FCS.
2.7. Tube Formation Assay. Experimental procedures on
formation of vascular-like structures by HUVECs on growth
factor-reduced Matrigel (BD Biosciences, NJ, USA) were
conducted as previously described [31]. Twenty-four-well
culture plates were coated with Matrigel according to the
manufacturer’s instructions. Serum-starved HUVECs were
seeded on coated plates at 5 × 104 cells/well in EBM-2
medium (Cambrex, Walkersville, Md. USA) with 0.5% fetal
bovine serum containing the indicated concentrations of
recombinant adiponectin, D-glucose or (D-mannitol as
osmolaric control) or 10 ng/mL VEGF and incubated at
37◦C for 48 h. In some experiments HUVECs were infected
with adenoviral constructs encoding β-galactosidase (Ad-
βgal) or dominant-negative AMPKα2 (Ad-dnAMPK) at a
multiplicity of infection of 50 for 24 h [27, 28, 31]. Tube
formation was observed using an inverted phase contrast
microscope (Nikon, Tokyo, Japan). Images were captured
with a video graphic system (DEI-750 CE Digital Output
Camera, Optronics, Goleta, CA). The degree of tube
formation was quantified by measuring the length of tubes
in 3 randomly chosen low power fields (×100) from each well
using the National Institutes of Health (NIH) image program
(NIH Image). Each experiment was repeated 3 times.
2.8. Statistical Analysis. Data are presented as mean ± SE.
Statistical analysis was performed by analysis of variance
(ANOVA). A value of P < 0.05 was accepted as statistically
significant.
3. Results
The mice analyzed in this study were male C57/BL6 (WT),
C57/BL6 treated with streptozocin (db1), as a model of
insulin deficiency, and Leprdb/db on the C57/BL6 back-
ground, as a model of metabolic syndrome and Type 2 dia-
betes (Figure 1(a)). Blood pressure did not diﬀer significantly
between the three groups (Table 1) on the day of surgery.
Significant diﬀerences were observed in body weight, plasma
glucose, and leptin levels between WT, db1, and Leprdb/db
mice (n = 6) (Table 1). Plasma adiponectin levels were sig-
nificantly elevated in db1 and Leprdb/db mice, relative to WT.
All mice survived the surgical induction of unilateral
left hind limb ischemia. After left femoral artery and vein
resection, the ratio of blood flow between the ischemic
and nonischemic hind limbs decreased to 0.18 ± 0.06 in
WT, 0.24 ± 0.04 in db1, and 0.27 ± 0.07 in Leprdb/db mice,
indicating that the severity of the induced ischemia was
comparable in the three groups. In WT mice, hind limb
blood flow perfusion increased to ∼60% of the nonischemic
limb by day 7 and ultimately returned to ∼70% of the
nonischemic limb by day 14. In contrast to WT mice, flow
recovery in both the db1 and Leprdb/db mice was impaired,
and the deficits in flow were statistically significant at the
14th day after surgery (Figures 1(b), 1(c), and 1(d)).
To investigate the extent of vascular remodeling on the
microcirculatory level in WT, db1, or Leprdb/db mice, quan-
titative analysis of capillary density in ischemic and contra
lateral adductor muscle of WT, db1, and Leprdb/db mice was
determined in histology sections harvested on postoperative
day 14. Figure 2(a) shows representative photomicrographs
of tissue harvested from WT, db1, or Leprdb/db mice on
postoperative day 14 that were immunostained with anti-
CD31, an antibody recognizing an endothelial cell marker
protein.
Compared with WT, both db1 and Leprdb/db tissue sec-
tions appeared to have fewer CD31-positive cells, and these
cells appeared to be distributed in a less organized pattern
compared with sections from WT animals. Quantitative
analysis of CD31-positive cells revealed that the ischemia-
induced increase in capillary density of the ischemic limb
relative to the contralateral limb was absent in both db1 and
Leprdb/db mice (Figure 2(b)), providing further evidence of
an impaired angiogenic response in these animals. At the
14-day time point following surgery, the ischemic adductor
muscle of both db1 and Leprdb/db mice showed significantly
fewer CD31-positive cells compared with ischemic muscle
from WT mice.
To investigate whether administration of adiponectin
improves vascular remodelling in WT, db1, and Leprdb/db
mice, adenoviral vectors expressing either adiponectin (Ad-
APN) or β-galactosidase (Ad-βgal) as a control were deliv-
ered via jugular vein, 3 days before hind limb surgery in each
experimental group. Ad-APN increased plasma adiponectin
levels 2.0-fold in WT mice, 1.9-fold in db1 mice, and 1.4-
fold in Leprdb/db mice compared to Ad-βgal-treated mice
(Table 2). As shown in Figure 3(a), a significant increase
in hind limb perfusion was revealed by laser doppler 14
days after hind limb surgery in WT mice that were treated
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Figure 1: Impaired angiogenic response in the ischemic hind limbs of db1 and Leprdb/db mice. (a) Schematic time course of the study design.
(b) A low perfusion signal (dark blue) was observed in the ischemic hind limb of db1 and Leprdb/db mice, whereas a higher perfusion signal
(white to red) was detected in WT mice on postoperative days 3, 7, and 14. (c) Quantitative analysis of the ischemic/nonischemic LDBF ratio
in WT and db1 mice before hind limb ischemia surgery, shortly after hind limb ischemia surgery, and on postoperative days 3, 7, and 14
(n = 6). ∗P < 0.01. (d) Quantitative analysis of the ischemic/nonischemic LDBF ratio in WT and Leprdb/db mice before hind limb ischemia
surgery, shortly after hind limb ischemia surgery, and on postoperative days 3, 7, and 14 (n = 6). #P < 0.05.
Table 1: Characteristics of WT, db1, and Leprdb/db mice.
Mouse strain BW sBP PG APN LP
WT 25.6± 0.9 94.2± 6.2 142± 22 7.1± 2.1 2560± 336
db1 19.0± 0.9 103.8± 17.6 426± 32 15.9± 2.4 561± 391
Leprdb/db 28.2± 1.7 96.5± 8.8 230± 21 17.0± 1.1 45957± 4090
Measurements were made on the day of surgery in mice at the age of 8 weeks that were fasted for 6 h (n = 6). Each value is means ± S.E. BW indicates body
weight (g); sBP: systolic blood pressure (mmHG); PG: plasma glucose (mg/dL); APN: adiponectin (μg/mL); LP: leptin (pg/mL).
with Ad-APN in comparison to control mice (both Ad-βgal-
treated and no adenovirus groups). In contrast, db1 mice
and Leprdb/+ mice showed no significant improvement in
hind limb perfusion following administration of adiponectin
(Figure 3(a)).
Quantitative analysis of capillary density in ischemic
adductor muscle of WT, db1, and Leprdb/db mice was deter-
mined in histological sections harvested from the ischemic
tissues for each experimental group on postoperative day
14 (Figure 3(b)). Immunostaining with anti-CD31 revealed
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Figure 2: Reduced capillary density in ischemic hind limbs of db1 and Leprdb/db mice. (a) Representative immunostaining of ischemic
tissues from WT, db1, and Leprdb/db mice with anti-CD31 monoclonal antibody (brown) on postoperative day 14. (b) Quantitative analysis
of capillary density in ischemic (= I) and contralateral (= C) adductor muscle ofWT, db1, and Leprdb/db mice on postoperative day 14 (n = 6
in each group). Capillary density was expressed as the number of capillaries per high power field (×400, (a)) and capillaries per muscle fiber
(b). ∗P < 0.01.
Table 2: Plasma adiponectin levels in each experimental group.
APN
(μg/mL)
3 days after gene transfer 10 days after gene transfer
Treatment Ad-βgal Ad-APN Ad-βgal Ad-APN
WT 7.7± 0.7 15.2± 3.5 8.2± 0.5 11.2± 1.2
db1 17.3± 6.4 29.8± 3.8 15.2± 3.5 22.7± 2.5
Leprdb/db 18.0± 3.8 23.6± 5.5 15.5± 2.1 16.9± 2.7
Measurements were made at 3 and 10 days following gene transfer in mice
that were fasted for 6 h (n = 6 for each group). APN: adiponectin (μg/mL).
Each value is mean ± S.E.
that adiponectin treatment significantly increased capillary
density in the ischemic adductor muscles of WT mice but
had no significant eﬀect on capillary density in db1 mice and
Leprdb/db mice.
The eﬀects of nonfractionated, recombinant adiponectin
at 30 μg/mL on endothelial cell death induced by mitogen
deprivation were examined at 5mmol/L, 10mmol/L and
30mmol/L glucose. An MTS-based assay (Figure 4(a))
showed that the adiponectin significantly decreased
endothelial cell death at high glucose concentrations
(30mmol/L). Transduction with an adenoviral vector
expressing dominant-negative AMPKα2 (Ad-dnAMPK)
abrogated the adiponectin-induced decrease in endothelial
cell death (Figure 4(b)) [19].
Adiponectin at a concentration of 30 μg/mL increased
endothelial cell diﬀerentiation into tube-like structures in
HUVECs plated on aMatrigel matrix (Figure 5(a)) at physio-
logical glucose concentrations (= 5mmol/L) consistent with
data previously described [12]. But this formation of tube-
like structures, seen at 5mmol/L glucose concentrations,
was abrogated despite the administration of adiponectin
(= 30 μg/mL) at elevated glucose levels (= 10mmol/L or
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Figure 3: No angiogenic response in ischemic hind limbs of db1 and Leprdb/db mice after adenovirus-mediated gene transfer of adiponectin.
(a) Adenoviral vectors expressing adiponectin or β-galactosidase (control) were delivered intravenously via the jugular vein at 3 days prior
to surgery. Quantitative analysis of ischemic/nonischemic LDBF ratio in WT, db1, and Leprdb/db mice without adenovirus-mediated gene
transfer (= control) or with adenovirus-mediated gene transfer (Ad-βgal and Ad-APN) on postoperative day 14. ∗P < 0.01 versus control
of WT, db1, and Leprdb/db mice without adenovirus-mediated gene transfer. (b) Quantitative analysis of capillary density in WT, db1 and
Leprdb/db mice in ischemic adductor muscle on postoperative day 14 (n = 6) without adenovirus-mediated gene transfer or with adenovirus-
mediated gene transfer (Ad-βgal and Ad-APN). Capillary density was expressed as the number of capillaries per high-power field (×400).
#P < 0.05.
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Figure 4: Eﬀects of adiponectin on HUVECs viability. (a) Eﬀect of adiponectin on endothelial cell death induced by serum starvation in
control medium (= 0.5% FCS), induced by VEGF (= 10 ng/mL), in 5mmol/L glucose medium, 10mmol/L glucose medium, and 30mmol/L
glucose mediumwithout or with adiponectin (= 30 μg/mL) for 48 hours. Cell viability was quantified with anMTS-based assay. VEGF served
as additional control. (b) Role of AMPK in the regulation of adiponectin-induced reduction of endothelial cell death in 5mmol/L glucose
medium, 10mmol/L glucose medium, and 30mmol/L glucose medium. HUVECs were transduced with an adenoviral vector expressing
β-galactosidase (Ad-βgal) (= control) or with an adenoviral vector expressing dominant-negative AMPKα2 (Ad-dnAMPK). After 24-hour
infection, cells were treated for 48 hours with adiponectin (= 30 μg/mL) under serum deprivation conditions. Cell viability was quantified
with an MTS-based assay.
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Figure 5: Eﬀects of adiponectin on endothelial cell diﬀerentiation into tube-like structures at 5mmol/L, 10mmol/L, and 30mmol/L glucose.
(a) Tube formation assays were performed. Representative cultures are shown as indicated. Adiponectin was used at a concentration of
30 μg/mL. (b) HUVECs were seeded on Matrigel-coated culture dishes in control medium (= 0.5% FCS) (= control), induced by VEGF (=
10 ng/mL), in 5mmol/L glucose medium, 10mmol/L glucose medium, and 30mmol/L glucose medium or in 5mmol/L, 10mmol/L, and
30mmol/L glucose in the presence of adiponectin (30 μg/mL). Incubation with VEGF served as additional control. Results are shown as
mean ± S.E. Results are expressed relative to control. ∗P < 0.01, #P < 0.05 versus control.
30mmol/L) compared to capillary formation at 10mmol/L
and 30mmol/L glucose without adiponectin (Figure 5(b)).
4. Discussion
Chronic hyperglycemia leads to microangiopathy, including
nephropathy, neuropathy, cardiomyopathy, and peripheral
vascular disease [32–35]. A few studies have examined the
eﬃciency of growth factor-mediated angiogenic repair in
these diseases. Previously, Rivard et al. or Schiekofer et al.
have shown that nonobese diabetic (NOD) mice, a model of
Type 1 diabetes or Leprdb/db mice, a mouse model of Type
2 diabetes, suﬀer from impaired angiogenic repair following
hind limb ischemia surgery [22–26, 36–39].
Therefore, the purpose of our study was twofold.
First, we compared ischemic-impaired angiogenic repair in
streptozocin-treated mice, a model of insulin deficiency, and
in Leprdb/db mice, a model of metabolic syndrome and Type
2 diabetes. Second, we evaluated the proangiogenic activity
of adiponectin in each of these models. Streptozocin-treated
mice or Leprdb/db mice showed decreased reperfusion and
capillary density in ischemic hind limbs following femoral
artery removal compared to WT mice. The exogenous
administration of adiponectin via adenovirus-mediated gene
transfer was not able to rescue the impairment in hind limb
capillary density in both db1 mice and Leprdb/db mice. In
contrast, wild-type mice injected with adiponectin displayed
an increase in hind limb reperfusion and an increase in
capillary density compared to control mice without injection
of adiponectin. This is consistent with previous reports that
show that adiponectin promotes angiogenesis due to its
ability to stimulate the AMPK-dependent pathways within
muscle in WT mice of a C57/BL6 background [18].
Migration of endothelial cells is a key event in angiogen-
esis that contributes to angiogenic repair in diabetic vascu-
lopathy. Adiponectin stimulates angiogenesis by promoting
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cross-talk between AMPK and Akt signaling in human
umbilical vein endothelial cells (HUVECs) and promotes
angiogenesis due to its ability to stimulate the AMPK-
dependent pathways within muscle in WT and adiponectin
knockout mice of a C57/BL6 background [12, 13]. In addi-
tion, antiapoptotic properties of adiponectin were shown on
the vasculature by revealing that recombinant adiponectin
dose dependently suppressed apoptosis and caspase-3 activ-
ity in HUVECs [14].
Our experiments highlight the importance of the adi-
ponectin AMPK signaling pathway for antiapoptotic prop-
erties of adiponectin by showing that the administration of
adiponectin significantly decreased endothelial cell death at
high glucose concentrations compared to nonadministration
of adiponectin. In addition, adiponectin increased endothe-
lial cell diﬀerentiation into tube-like structures in HUVECs
plated on a Matrigel matrix at physiological glucose concen-
trations, but this eﬀect was abrogated after the incubation of
HUVECs at elevated glucose concentrations. Furthermore,
external administration of adiponectin to db1 or Leprdb/db
mice that underwent hind limb ischemia did not significantly
improve angiogenic repair in comparison to WT mice.
The reasons for the failure of adiponectin to facilitate
an increase in capillary density after hind limb ischemia
surgery, in db1 or Leprdb/db mice, need further investigation.
However, one reason might simply be that the significantly
elevated glucose levels in db1 or Leprdb/db mice, compared
to WT mice, lead to abrogation of previously reported
proangiogenic eﬀects of adiponectin as was shown by our in
vitro experiments [12, 13].
We also found that streptozocin-treated db1 or Leprdb/db
mice had higher plasma adiponectin concentrations than
WT mice according to our baseline data (Table 1). Our
results confirm recent reports in an animal model for Type
1 diabetes, which showed that plasma adiponectin levels
are higher in Type 1 diabetic patients than in healthy con-
trol subjects [40–42]. Follow-up observational studies also
showed that higher adiponectin concentrations are associ-
ated with an increased risk of incident microvascular compli-
cations in Type 1 diabetes [33, 34]. This finding was contrary
to those reported for the association between adiponectin
and macrovascular complications in Type 2 diabetes, as
plasma adiponectin levels have repeatedly been shown to be
lower in patients with insulin resistance or macrovascular
complications than in control subjects [4, 35]. It is therefore
highly likely that adiponectin is regulated diﬀerently in
Type 1 diabetes than it is in Type 2 diabetes. It remains
to be clarified whether elevated levels of adiponectin are
pathogenically related to the development of microvascular
complications or represent a beneficial counterregulatory
response in Type 1 diabetes.
Surprisingly and in contrast to previously reported data,
Leprdb/db mice had higher plasma adiponectin concentra-
tions than WT mice according to our baseline data [9,
10]. We surmise that as a consequence of these elevated
adiponectin levels, additional administration of adiponectin
failed to improve angiogenic repair in this animal model.
We speculate that these mice may show elevated adiponectin
levels as a result of adiponectin resistance caused by a defect
on the adiponectin receptor level that could be linked to the
lack of a functional leptin receptor [43, 44]. But this requires
further investigation.
Our observations demonstrate that external administra-
tion of adiponectin may not be useful in the treatment of
angiogenic repair-related complications of Type 1 or Type 2
diabetes with persistent hyperglycemia.
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